Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and... ORIGINAL ARTICLE Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel Makoto Kawaishi, MD,* Yutaka Fujiwara, MD,† Tomoya Fukui, MD,* Terufumi Kato, MD,* Kazuhiko Yamada, MD,† Yuichiro Ohe, MD, PhD,† Hideo Kunitoh, MD, PhD,† Ikuo Sekine, MD, PhD,† Noboru Yamamoto, MD, PhD,† Hiroshi Nokihara, MD, PhD,† Takeshi Watabe, PhD,‡ Yuji Shimoda, PhD,‡ Tokuzo Arao, MD, PhD,§ Kazuto Nishio, MD, PhD,§ Tomohide Tamura, MD† and Fumiaki Koizumi, MD, PhD* ngiogenesis plays a critical role in the growth and me- Introduction: Circulating endothelial cells (CECs) increase in can- Atastasis of solid tumors. The clinical importance of cer patients and play an important role in tumor neovascularization. angiogenesis in human tumors has been demonstrated by Methods: This study was designed to investigate the role of CEC as several reports indicating a positive relationship between the a marker for predicting the effectiveness of a carboplatin plus blood vessel density in the tumor mass and poor prognosis, paclitaxel based first line chemotherapy in advanced non-small cell i.e., survival, in patients with various types of cancers includ- lung cancer (NSCLC). 2–6 ing non-small cell lung cancer (NSCLC). Furthermore, Results: The CEC count in 4 ml of peripheral blood before starting http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel

Koizumi, Fumiaki
Journal of Thoracic Oncology , Volume 4 (2) – Feb 1, 2009
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/circulating-endothelial-cells-in-non-small-cell-lung-cancer-patients-TbZq6XlXCu

References (47)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318193030d
pmid
19179898
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel Makoto Kawaishi, MD,* Yutaka Fujiwara, MD,† Tomoya Fukui, MD,* Terufumi Kato, MD,* Kazuhiko Yamada, MD,† Yuichiro Ohe, MD, PhD,† Hideo Kunitoh, MD, PhD,† Ikuo Sekine, MD, PhD,† Noboru Yamamoto, MD, PhD,† Hiroshi Nokihara, MD, PhD,† Takeshi Watabe, PhD,‡ Yuji Shimoda, PhD,‡ Tokuzo Arao, MD, PhD,§ Kazuto Nishio, MD, PhD,§ Tomohide Tamura, MD† and Fumiaki Koizumi, MD, PhD* ngiogenesis plays a critical role in the growth and me- Introduction: Circulating endothelial cells (CECs) increase in can- Atastasis of solid tumors. The clinical importance of cer patients and play an important role in tumor neovascularization. angiogenesis in human tumors has been demonstrated by Methods: This study was designed to investigate the role of CEC as several reports indicating a positive relationship between the a marker for predicting the effectiveness of a carboplatin plus blood vessel density in the tumor mass and poor prognosis, paclitaxel based first line chemotherapy in advanced non-small cell i.e., survival, in patients with various types of cancers includ- lung cancer (NSCLC). 2–6 ing non-small cell lung cancer (NSCLC). Furthermore, Results: The CEC count in 4 ml of peripheral blood before starting

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Feb 1, 2009

There are no references for this article.